Literature DB >> 3141198

Interferon exerts a cytotoxic effect on primary human myeloma cells.

S Einhorn1, J O Fernberg, D Grandér, R Lewensohn.   

Abstract

A dye exclusion method was used for testing the sensitivity of primary human myeloma and normal bone-marrow cells to interferon (IFN). Following 4 days of incubation with 5000 units/ml of natural (n) IFN-alpha, there was a greater than 90% decrease in the number of viable myeloma cells in cultures from some patients, whereas myeloma cells from other patients showed intermediate or no sensitivity to IFN. The number of viable non-malignant bone-marrow cells (from the same patients) following a 4-day exposure to nIFN-alpha (5000 units/ml) decreased by 10-60%. Exposure of malignant and non-malignant bone-marrow cells to natural beta- and recombinant alpha- and gamma-IFN, also induced a decrease in the number of viable cells. The decreased number of viable myeloma cells could be observed already after 1 day of exposure to IFN-alpha in vitro. To test whether inhibition of proliferation could account for the observed effects, proliferation, as measured by [3H]thymidine uptake, was studied in some experiments. Only approx. 1-2% of the myeloma cells were labeled with [3H]thymidine during the 4 days of culture in vitro, whereas the proportion of labeled non-malignant cells was approx. 40%. Thus, the IFN-induced reduction of cell number in normal bone-marrow cells could possibly be attributed to a cell multiplication inhibitory effect of IFN, whereas the effect observed in myeloma cells cannot be attributed to cell multiplication inhibition. To test the possibility that the reduction in the number of myeloma cells could be attributed to the activity of autologous cytotoxic T-cells, NK-cells or macrophages, these cells were depleted in some experiments. Depletion of these cells did not, however, influence the IFN-induced decrease in the number of viable myeloma cells. We thus conclude that IFN can reduce the number of viable tumor cells by a cytotoxic effect, unrelated to cell multiplication inhibition.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141198     DOI: 10.1016/0277-5379(88)90342-2

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  4 in total

1.  Efficacy of peptide bound m-L-sarcolysin (peptichemio) on melphalan resistant human myeloma cells in vitro.

Authors:  R Lewensohn; J O Fernberg; H Ehrsson; G Merlini
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

2.  Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression.

Authors:  D F Jelinek; K M Aagaard-Tillery; B K Arendt; T Arora; R C Tschumper; J J Westendorf
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

Review 3.  Interferon treatment of human malignancies--a short review.

Authors:  S Einhorn; H Strander
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

Review 4.  The treatment of multiple myeloma--an important MRC trial.

Authors:  P W Johnson; P J Selby
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.